Hyperubiquitination of proteins in dilated cardiomyopathy - PubMed (original) (raw)
Hyperubiquitination of proteins in dilated cardiomyopathy
John Weekes et al. Proteomics. 2003 Feb.
Abstract
Protein degradation by the ubiquitin-proteasome pathway plays an important role in a variety of fundamental cellular processes, including cell cycle regulation, transcription, antigen processing and muscle remodelling. Research into disorders associated with the ubiquitin-proteasome system has been mainly in the field of neurodegenerative diseases. It is however becoming increasingly apparent that defects in the system are responsible for a number of non-neurological pathologies. Based on initial observations made as part of a proteomic analysis of an animal model of dilated cardiomyopathy (DCM) which indicated increased activity of the ubiquitin-proteasome system, we sought to determine whether this system was perturbed in hearts of human DCM patients. We studied explanted hearts from 12 DCM, 9 ischaemic (IHD) and 12 unused donor hearts. Protein expression was examined using two-dimensional polyacrylamide gel electrophoresis, Western blotting and immunohistochemistry. Expression of mRNA was examined using real-time quantitative polymerase chain reaction. Ubiquitinated proteins were affinity purified using a ubiquitin-binding column and identified using peptide mass fingerprinting. All DCM hearts showed significantly higher expression of certain key enzymes of the ubiquitin-proteasome pathway. mRNA expression of ubiquitin carboxyl-terminal hydrolase (UCH) was significantly higher (5.4-fold) in DCM hearts than in control hearts. Myocytes in sections from DCM hearts stained positively for UCH, whereas control hearts were negative. Overall protein ubiquitination was increased two-fold in DCM relative to IHD hearts and five-fold relative to donor hearts. The ubiquitination of a number of distinct proteins was greatly enhanced in DCM hearts as revealed by anti-ubiquitin Western blots. A number of these proteins were identified using affinity purification and matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.
Similar articles
- Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy.
Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJ, Yacoub MH, Evans PC. Birks EJ, et al. Cardiovasc Res. 2008 Aug 1;79(3):472-80. doi: 10.1093/cvr/cvn083. Epub 2008 Mar 28. Cardiovasc Res. 2008. PMID: 18375498 - Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts.
Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Makarenko I, et al. Circ Res. 2004 Oct 1;95(7):708-16. doi: 10.1161/01.RES.0000143901.37063.2f. Epub 2004 Sep 2. Circ Res. 2004. PMID: 15345656 - Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy.
Szotowski B, Goldin-Lang P, Antoniak S, Bogdanov VY, Pathirana D, Pauschinger M, Dörner A, Kuehl U, Coupland S, Nemerson Y, Hummel M, Poller W, Hetzer R, Schultheiss HP, Rauch U. Szotowski B, et al. J Am Coll Cardiol. 2005 Apr 5;45(7):1081-9. doi: 10.1016/j.jacc.2004.12.061. J Am Coll Cardiol. 2005. PMID: 15808768 - Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart.
Serneri GG, Cecioni I, Vanni S, Paniccia R, Bandinelli B, Vetere A, Janming X, Bertolozzi I, Boddi M, Lisi GF, Sani G, Modesti PA. Serneri GG, et al. Circ Res. 2000 Mar 3;86(4):377-85. doi: 10.1161/01.res.86.4.377. Circ Res. 2000. PMID: 10700441 - Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy.
Abraham D, Hofbauer R, Schäfer R, Blumer R, Paulus P, Miksovsky A, Traxler H, Kocher A, Aharinejad S. Abraham D, et al. Circ Res. 2000 Oct 13;87(8):644-7. doi: 10.1161/01.res.87.8.644. Circ Res. 2000. PMID: 11029398 Clinical Trial.
Cited by
- Transcription factor EB, a promising therapeutic target in cardiovascular disease.
Yan X, Yang L, Fu X, Luo X, Wang C, Xie QP, OuYang F. Yan X, et al. PeerJ. 2024 Oct 11;12:e18209. doi: 10.7717/peerj.18209. eCollection 2024. PeerJ. 2024. PMID: 39403192 Free PMC article. Review. - Genetic blockade of the activation of 26S proteasomes by PKA is well tolerated by mice at baseline.
Yang L, Ahammed MS, Wu P, Sternburg JO, Liu J, Wang X. Yang L, et al. Am J Cardiovasc Dis. 2024 Apr 15;14(2):90-105. doi: 10.62347/NSWR6869. eCollection 2024. Am J Cardiovasc Dis. 2024. PMID: 38764549 Free PMC article. - Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition.
Wu Q, Liu WJ, Ma XY, Chang JS, Zhao XY, Liu YH, Yu XY. Wu Q, et al. Acta Pharmacol Sin. 2024 Apr;45(4):738-750. doi: 10.1038/s41401-023-01191-7. Epub 2023 Dec 14. Acta Pharmacol Sin. 2024. PMID: 38097716 - S14-Phosphorylated RPN6 Mediates Proteasome Activation by PKA and Alleviates Proteinopathy.
Yang L, Parajuli N, Wu P, Liu J, Wang X. Yang L, et al. Circ Res. 2023 Sep 15;133(7):572-587. doi: 10.1161/CIRCRESAHA.123.322887. Epub 2023 Aug 29. Circ Res. 2023. PMID: 37641975 Free PMC article. - Ubiquitin, p62, and Microtubule-Associated Protein 1 Light Chain 3 in Cardiomyopathy.
Eto R, Kawano H, Matsuyama-Matsuu M, Matsuda K, Ueki N, Nakashima M, Okano S, Ishijima M, Kawakatsu M, Watanabe J, Yoshimuta T, Ikeda S, Maemura K. Eto R, et al. Circ Rep. 2023 Jul 6;5(8):323-330. doi: 10.1253/circrep.CR-23-0058. eCollection 2023 Aug 10. Circ Rep. 2023. PMID: 37564875 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources